PT1592384E - Cop-1 para o tratamento de doenças inflamatórias do intestino - Google Patents

Cop-1 para o tratamento de doenças inflamatórias do intestino

Info

Publication number
PT1592384E
PT1592384E PT47034624T PT04703462T PT1592384E PT 1592384 E PT1592384 E PT 1592384E PT 47034624 T PT47034624 T PT 47034624T PT 04703462 T PT04703462 T PT 04703462T PT 1592384 E PT1592384 E PT 1592384E
Authority
PT
Portugal
Prior art keywords
cop
treatment
inflammatory bowel
bowel diseases
diseases
Prior art date
Application number
PT47034624T
Other languages
English (en)
Inventor
Rina Aharoni
Ruth Arnon
Basak Kayhan
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of PT1592384E publication Critical patent/PT1592384E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT47034624T 2003-01-21 2004-01-20 Cop-1 para o tratamento de doenças inflamatórias do intestino PT1592384E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44113603P 2003-01-21 2003-01-21

Publications (1)

Publication Number Publication Date
PT1592384E true PT1592384E (pt) 2013-01-28

Family

ID=32771907

Family Applications (1)

Application Number Title Priority Date Filing Date
PT47034624T PT1592384E (pt) 2003-01-21 2004-01-20 Cop-1 para o tratamento de doenças inflamatórias do intestino

Country Status (14)

Country Link
US (1) US8008258B2 (pt)
EP (1) EP1592384B1 (pt)
AU (1) AU2004206120B2 (pt)
CA (1) CA2513567C (pt)
DK (1) DK1592384T3 (pt)
ES (1) ES2397836T3 (pt)
MX (1) MXPA05007711A (pt)
NO (1) NO333579B1 (pt)
NZ (1) NZ569331A (pt)
PT (1) PT1592384E (pt)
RU (1) RU2339397C2 (pt)
SI (1) SI1592384T1 (pt)
WO (1) WO2004064717A2 (pt)
ZA (1) ZA200505733B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
MXPA04005433A (es) * 2001-12-04 2004-10-11 Teva Pharma Proceso para la medicion de la potencia de acetato de glatiramero.
JP2007536278A (ja) * 2004-05-07 2007-12-13 ペプチミューン,インコーポレイテッド ランダム共重合体を用いる疾患の治療方法
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
WO2006029411A2 (en) * 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
EP1838326A4 (en) * 2005-02-02 2009-09-30 Teva Pharma PROCESS FOR PREPARING POLYPEPTIDE MIXTURES BY HYDROGENOLYSIS
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
US20110212052A1 (en) * 2008-07-25 2011-09-01 The Johns Hopkins University Methods and compositions of treating and preventing autoimmune diseases
RS52885B (en) 2009-08-20 2014-02-28 Yeda Research And Development Co. Ltd. LOW-FREQUENCY GLATIRAMER ACETATOM THERAPY
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
RU2722357C2 (ru) 2010-07-26 2020-05-29 Кью Байолоджикс Инк. Иммуногенные противовоспалительные композиции
EA025780B1 (ru) 2010-10-11 2017-01-30 Тева Фармасьютикал Индастриз Лтд. Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
TW201326399A (zh) 2011-10-10 2013-07-01 Teva Pharma 用於預測對格拉替雷(glatiramer)醋酸鹽之臨床反應之單核苷酸多型性之判定
MX2015004563A (es) 2012-10-10 2015-07-14 Teva Pharma Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
EP3137108A4 (en) 2014-05-02 2017-09-27 Qu Biologics Inc Anti-microbial immunomodulation
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
EP3478300B1 (en) 2016-06-30 2022-08-24 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
EP3600553A4 (en) 2017-03-26 2020-09-02 Mapi Pharma Ltd. GLATIRAMER DEPOT SYSTEMS FOR TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS
JP7000458B2 (ja) 2017-05-15 2022-02-10 ステム セル メディスン リミテッド 長時間作用性グラチラマー及び脂肪由来幹細胞での多発性硬化症の治療
CA3062123A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
EP1098902A4 (en) * 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES
WO2000005249A2 (en) 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
EP2090583B1 (en) 1998-09-25 2011-07-13 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2000020010A1 (en) * 1998-10-02 2000-04-13 Yeda Research And Development Co., Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
CA2355400A1 (en) * 1998-11-12 2000-05-18 Yeda Research And Development Co., Ltd. Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd
CA2396871A1 (en) * 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
JP2003522799A (ja) 2000-02-18 2003-07-29 イエダ・リサーチ・アンド・ディベロップメント・カンパニー・リミテッド・アット・ザ・ウェイズマン・インスティテュート・オブ・サイエンス コポリマー1の経口、経鼻および経肺投与製剤
AU2003204344A1 (en) * 2002-05-23 2003-12-11 Milder, Dan George Compositions and methods for the treatment of autoimmune diseases and neurological disorders
WO2006029411A2 (en) * 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof

Also Published As

Publication number Publication date
RU2339397C2 (ru) 2008-11-27
AU2004206120A1 (en) 2004-08-05
RU2005126412A (ru) 2006-01-27
EP1592384A2 (en) 2005-11-09
EP1592384B1 (en) 2012-10-31
NO20053860L (no) 2005-10-20
AU2004206120B2 (en) 2009-09-24
US20060264354A1 (en) 2006-11-23
NZ569331A (en) 2010-08-27
US8008258B2 (en) 2011-08-30
ZA200505733B (en) 2006-10-25
ES2397836T3 (es) 2013-03-11
NO20053860D0 (no) 2005-08-18
MXPA05007711A (es) 2005-09-30
CA2513567C (en) 2012-10-23
EP1592384A4 (en) 2008-12-31
WO2004064717A2 (en) 2004-08-05
NO333579B1 (no) 2013-07-15
DK1592384T3 (da) 2012-12-17
WO2004064717A3 (en) 2005-10-13
SI1592384T1 (sl) 2013-03-29
CA2513567A1 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
EP1592384A4 (en) COP 1 FOR THE TREATMENT OF INFLAMMABLE ENDURANCE
EP1592384A3 (en) Cop 1 for treatment of inflammatory bowel diseases
IL152127A0 (en) Probiotic compositions for the treatment of inflammatory bowel disease
HUP0303622A3 (en) Emedies for inflammatory bowel diseases
PL362711A1 (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases
PL1608965T3 (pl) Sposoby wyznaczania skuteczności terapii chorób zapalnych jelit
HK1082256A1 (en) New compounds, compositions and methods for treatment of inflammatory diseases and conditions
EP1581119A4 (en) COMPOSITIONS AND METHODS FOR THERAPY AND DIAGNOSIS FOR INFLAMMATORY BOWEL DISEASE
EP1578385A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF INFLAMMATORY INTESTINAL DISEASES
IL169602A0 (en) Methods of treating lung diseases
GB0312832D0 (en) 2-amino-pyridine derivatives useful for the treatment of diseases
IL155092A0 (en) Compounds useful in the treatment of inflammatory diseases
IL175535A0 (en) Compositions for treatment of neurodegenerative diseases
GB0329874D0 (en) Compounds useful for the treatment of diseases
EP1680145A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
EP1611120A4 (en) NEW M THODES FOR THE TREATMENT OF INFLAMMATORY DISEASES
GB0305150D0 (en) Use of therapeutic compounds
GB0320238D0 (en) Treatment of disease
EP1708961A4 (en) TREATMENT OF INFLAMMATORY ENDURANCE WITH ANTI-IP-10 ANTIBODIES
AU2002309180A1 (en) Composition and kit for the treatment of inflammatory bowel diseases
EP1444983A4 (en) AGENTS FOR THE TREATMENT OF INFLAMMATORY ABDOMINAL DISEASES
GB0526394D0 (en) Treatment of inflammatory diseases
AU2003251650A8 (en) Screening for agents suitable for treatment of leukocyte associated inflammatory diseases
EP1513550A4 (en) NEW BACTERIUM FOR THE TREATMENT OF DISEASES
TWI315984B (en) Agent for treatment of anal disease